MetaCap

Ardelyx (ARDX) vs Ironwood Pharmaceuticals (IRWD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ironwood Pharmaceuticals (IRWD) has outperformed Ardelyx (ARDX) over the past year, gaining 48.7% versus a loss of 44.8%. Over five years, ARDX leads with a +234.8% price change compared with -57.9% for IRWD. Ironwood Pharmaceuticals is the larger company by market cap ($778.1 million vs $751.6 million), about 1.0 times the size, while Ardelyx is growing revenue faster (+22.1% vs -15.7%).

On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (3.0x vs 18.9x for Ardelyx). Ironwood Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.1% versus -15.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARDX-44.83%IRWD+48.73%
+76%+12%-53%
Nov 21, 20251 yearNov 20, 2026
ARDX+199.00%IRWD-59.83%
+922%+389%-144%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARDX versus IRWD key metrics
MetricARDXIRWD
Share price$2.99$4.70
Market cap$751.60M$778.09M
1-day change-2.29%-0.21%
YTD return-48.71%+39.47%
1-year return-44.83%+48.73%
5-year return+234.83%-57.89%
P/E ratio (TTM)—5.22
Forward P/E18.923.00
EPS (TTM)$-0.23$0.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$407.32M$296.15M
Revenue growth (YoY)+22.09%-15.72%
Net income (latest FY)$-61.60M$24.02M
Gross margin90.29%—
Operating margin-10.06%33.26%
Net margin-15.12%8.11%
52-week high$8.40$5.78
52-week low$2.80$2.95
Distance from 52-week high-64.40%-18.69%
Analyst consensusstrong_buybuy
Avg. price target upside+318.06%+31.49%
Average volume4.46M2.15M
Shares outstanding251.37M165.55M
Employees489100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IRWD has outperformed ARDX by 93.6 percentage points over the past year.
  • Ironwood Pharmaceuticals is more profitable, keeping 8.1 cents of every revenue dollar as net income versus -15.1 cents for Ardelyx.
  • Ardelyx grew revenue faster in its latest fiscal year (+22.09% vs -15.72%).

About Ardelyx

ARDX stock →

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees

About Ironwood Pharmaceuticals

IRWD stock →

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

ARDX vs IRWD FAQ

Which is bigger, Ardelyx or Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $778.09M compared with $751.60M for Ardelyx (ARDX).

Which stock has performed better over the past year, ARDX or IRWD?

IRWD returned +48.73% over the past 12 months, compared with -44.83% for ARDX (price return, excluding dividends). Past performance does not predict future results.

Are Ardelyx and Ironwood Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons